This was a multicenter study conducted at six centers in the USA (University Hospitals of Cleveland, Cleveland, OH; Baylor College of Medicine, Houston, TX; Children's Hospital of Philadelphia, Philadelphia, PA; Children's Hospital of Iowa, Iowa City, IA; Children's Hospital and Research Center Oakland, Oakland, CA; and Amgen Inc., Thousand Oaks, CA).
Pharmacokinetic evaluation of darbepoetin alfa for the treatment of pediatric patients with chemotherapy-induced anemia†
Article first published online: 21 NOV 2006
Copyright © 2006 Wiley-Liss, Inc.
Pediatric Blood & Cancer
Volume 49, Issue 5, pages 687–693, 15 October 2007
How to Cite
Blumer, J., Berg, S., Adamson, P. C., Loew, T., Rossi, G. and Hastings, C. (2007), Pharmacokinetic evaluation of darbepoetin alfa for the treatment of pediatric patients with chemotherapy-induced anemia. Pediatr. Blood Cancer, 49: 687–693. doi: 10.1002/pbc.21079
- Issue published online: 21 AUG 2007
- Article first published online: 21 NOV 2006
- Manuscript Accepted: 15 SEP 2006
- Manuscript Received: 19 MAY 2006
- Amgen Inc. (Thousand Oaks, CA). Grant Number: 20000126
- darbepoetin alfa;
Cancer patients undergoing chemotherapy often develop anemia, which can increase the risk for transfusions and fatigue. The recombinant erythropoiesis-stimulating agent darbepoetin alfa can effectively treat chemotherapy-induced anemia (CIA) in adults, but limited data are available regarding its use in pediatric cancer patients. The goals of this phase 1, open-label, uncontrolled study were to assess the pharmacokinetic profile and safety of darbepoetin alfa in pediatric patients with CIA.
Pediatric patients with nonmyeloid malignancies and CIA received up to six doses of darbepoetin alfa 2.25 mcg/kg subcutaneously. After the first dose, the pharmacokinetic properties of darbepoetin alfa were assessed during a 14-day sampling period. All subsequent doses were given weekly with predose blood samples collected before study drug administration.
After a single dose of darbepoetin alfa, the mean (SD) peak serum concentration was 10.5 (3) ng/ml, and the median time to peak concentration was 71.4 hr. Darbepoetin alfa exhibited a mean (SD) terminal half-life of 49.4 (32) hr. Upon repeated weekly administration, no evidence of darbepoetin alfa accumulation was observed though there was high intra- and inter-individual variability. In addition, darbepoetin alfa was well tolerated; some study patients experienced increases in hemoglobin.
The pharmacokinetic profile of darbepoetin alfa indicated that it was slowly absorbed and exhibited a long terminal half-life in these pediatric study patients with CIA. Pediatr Blood Cancer 2007;49:687–693. © 2006 Wiley-Liss, Inc.